These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10189261)

  • 1. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
    Stevens RE; Limsakun T; Evans G; Mason DH
    J Pharm Sci; 1998 Dec; 87(12):1531-4. PubMed ID: 10189261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
    Konsil J; Dechasathian S; Mason DH; Stevens RE
    J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy.
    Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW
    Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
    Garnett WR; Gilbert TD; O'Connor P
    Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
    Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
    Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A
    Epilepsy Res; 1998 Nov; 32(3):371-8. PubMed ID: 9839777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation.
    McLean A; Browne S; Zhang Y; Slaughter E; Halstenson C; Couch R
    J Clin Pharmacol; 2001 Feb; 41(2):183-6. PubMed ID: 11210399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of dosing frequency of carbamazepine with a slow-release preparation.
    Sivenius J; Heinonen E; Lehto H; Järvensivu P; Anttila M; Ylinen A; Riekkinen P
    Epilepsy Res; 1988; 2(1):32-6. PubMed ID: 3197677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
    Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ
    Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.
    Wilding IR; Davis SS; Hardy JG; Robertson CS; John VA; Powell ML; Leal M; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1991 Nov; 32(5):573-9. PubMed ID: 1954073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
    Zhao Q; Janssens L; Verhaeghe T; Brashear HR; Truyen L
    Curr Med Res Opin; 2005 Oct; 21(10):1547-54. PubMed ID: 16238894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group.
    Neurology; 1995 Sep; 45(9):1703-7. PubMed ID: 7675230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
    Mahmood I; Chamberlin N
    Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.